A novel inhibitor of Chlamydophila pneumoniae protein kinase D (PknD) inhibits phosphorylation of CdsD and suppresses bacterial replication

BMC Microbiology

Volumn 9, Issue , 2009, Pages

  Johnson, Dustin L ^a,b   Stone, Chris B ^a,b   Bulir, David C ^a,b   Coombes, Brian K ^a,b   Mahony, James B ^a,b  

^a MCMASTER UNIVERSITY   (Canada)

^b MCMASTER UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL PROTEIN; CDSD PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE KINASE; OXINDOLE; PROTEIN KINASE D; UNCLASSIFIED DRUG; INDOLE DERIVATIVE; PROTEIN KINASE C; PROTEIN KINASE INHIBITOR;

ARTICLE; AUTOPHOSPHORYLATION; BACTERIAL COUNT; BACTERIAL GROWTH; CHLAMYDOPHILA PNEUMONIAE; CONTROLLED STUDY; ELECTRON MICROSCOPE; EUKARYOTE; GROWTH INHIBITION; HUMAN; HUMAN CELL; IN VITRO STUDY; INHIBITION KINETICS; NONHUMAN; PROTEIN PHOSPHORYLATION; SALMONELLA ENTERICA; SALMONELLA TYPHIMURIUM; SCREENING; SEROTYPE; SIGNAL TRANSDUCTION; CELL SURVIVAL; CHLAMYDOPHILA INFECTION; DRUG ANTAGONISM; ENZYMOLOGY; GENE EXPRESSION REGULATION; GENETICS; GROWTH, DEVELOPMENT AND AGING; HELA CELL; METABOLISM; MICROBIOLOGY; PHOSPHORYLATION;

BACTERIA (MICROORGANISMS); CHLAMYDIA TRACHOMATIS; CHLAMYDOPHILA PNEUMONIAE; EUKARYOTA; SALMONELLA ENTERICA;

BACTERIAL PROTEINS; CELL SURVIVAL; CHLAMYDOPHILA INFECTIONS; CHLAMYDOPHILA PNEUMONIAE; GENE EXPRESSION REGULATION, BACTERIAL; HELA CELLS; HUMANS; INDOLES; PHOSPHORYLATION; PROTEIN KINASE C; PROTEIN KINASE INHIBITORS;

EID: 70449365796     PISSN: 14712180     EISSN: 14712180     Source Type: Journal    
DOI: 10.1186/1471-2180-9-218     Document Type: Article

References (57)

1. Chlamydia pneumoniae as a respiratory pathogen. DL Hahn AA Azenabor WL Beatty GI Byrne, Front Biosci 2002 7 66 e76 10.2741/hahn 11861211
2. Asthmatic persons are prone to the persistence of Chlamydia pneumoniae antibodies. M Paldanius R Juvonen M Leinonen A Bloigu S Silvennoinen-Kassinen P Saikku, Diagn Microbiol Infect Dis 2007 59 117 122 10.1016/j.diagmicrobio.2007. 04.004 17572038
3. Asthma and atypical bacterial infection. ER Sutherland RJ Martin, Chest 2007 132 1962 1966 10.1378/chest.06-2415 18079229
4. Chlamydia pneumoniae and cardiovascular disease. LA Campbell CC Kuo JT Grayston, Emerg Infect Dis 1998 4 571 579 10.3201/eid0404.980407 9866733
5. Background and current knowledge of Chlamydia pneumoniae and atherosclerosis. JT Grayston, J Infect Dis 2000 181 Suppl 3 402 S410 10.1086/315596 10839724
6. Chlamydia pneumoniae and atherosclerosis. JT Grayston, Clin Infect Dis 2005 40 1131 1132 10.1086/428739 15791512
7. Chlamydia pneumoniae arthritis in a patient with common variable immunodeficiency. O Ardeniz O Gulbahar N Mete C Cicek OK Basoglu A Sin A Kokuludag, Ann Allergy Asthma Immunol 2005 94 504 508 15875533
8. Chlamydophila pneumoniae and the etiology of late-onset Alzheimer's disease. BJ Balin CS Little CJ Hammond DM Appelt JA Whittum-Hudson HC Gerard AP Hudson, J Alzheimers Dis 2008 13 371 380 18487846
9. Chlamydophila (Chlamydia)pneumoniae in the Alzheimer's brain. HC Gerard U Dreses-Werringloer KS Wildt S Deka C Oszust BJ Balin WH Frey EZ Bordayo JA Whittum-Hudson AP Hudson, FEMS Immunol Med Microbiol 2006 48 355 366 10.1111/j.1574-695X.2006.00154.x 17052268
10. Molecular detection of Parachlamydia-like organisms in cerebrospinal fluid of patients with multiple sclerosis. C Contini S Seraceni R Cultrera M Castellazzi E Granieri E Fainardi, Mult Scler 2008 14 564 566 10.1177/1352458507085796 18562511
11. Under the Microscope: Focus on Chlamydia pneumoniae Infection and Multiple Sclerosis. E Fainardi M Castellazzi S Seraceni E Granieri C Contini, Curr Neurovasc Res 2008 5 60 70 10.2174/156720208783565609 18289023
12. Infection with Chlamydia pneumoniae and risk of multiple sclerosis. KL Munger RW Peeling MA Hernan L Chasan-Taber MJ Olek SE Hankinson D Hunter A Ascherio, Epidemiology 2003 14 141 147 10.1097/00001648-200303000-00006 12606878 (Pubitemid 40417099)
13. Multiple sclerosis: an infectious syndrome involving Chlamydophila pneumoniae. CW Stratton DB Wheldon, Trends Microbiol 2006 14 474 479 10.1016/j.tim.2006.09.002 16996738
14. Replication of Chlamydia pneumoniae in vitro in human macrophages, endothelial cells, and aortic artery smooth muscle cells. CA Gaydos JT Summersgill NN Sahney JA Ramirez TC Quinn, Infect Immun 1996 64 1614 1620 8613369
15. A Chlamydia pneumoniae infection model using established human lymphocyte cell lines. H Yamaguchi S Haranaga H Friedman JA Moor KE Muffly Y Yamamoto, FEMS Microbiol Lett 2002 216 229 234 10.1111/j.1574-6968.2002.tb11440.x 12435507
16. Chlamydia pneumoniae resists antibiotics in lymphocytes. H Yamaguchi H Friedman M Yamamoto K Yasuda Y Yamamoto, Antimicrob Agents Chemother 2003 47 1972 1975 10.1128/AAC.47.6.1972-1975.2003 12760877
17. Phagocytes transmit Chlamydia pneumoniae from the lungs to the vasculature. J Gieffers G van Zandbergen J Rupp F Sayk S Kruger S Ehlers W Solbach M Maass, Eur Respir J 2004 23 506 510 10.1183/09031936.04.00093304 15083745
18. [Choice of antimicrobial drug for infections caused by Chlamydia trachomatis and Chlamydophila pneumoniae]. L Zele-Starcevic V Plecko A Budimir S Kalenic, Acta Med Croatica 2004 58 329 333 15700690
19. Mutations in a 23S rRNA gene of Chlamydia trachomatis associated with resistance to macrolides. OY Misyurina EV Chipitsyna YP Finashutina VN Lazarev TA Akopian AM Savicheva VM Govorun, Antimicrob Agents Chemother 2004 48 1347 1349 10.1128/AAC.48.4.1347-1349.2004 15047540
20. Frequency of spontaneous mutations that confer antibiotic resistance in Chlamydia spp. R Binet AT Maurelli, Antimicrob Agents Chemother 2005 49 2865 2873 10.1128/AAC.49.7.2865-2873.2005 15980362
21. Frequency of development and associated physiological cost of azithromycin resistance in Chlamydia psittaci 6BC and C. trachomatis L2. R Binet AT Maurelli, Antimicrob Agents Chemother 2007 51 4267 4275 10.1128/AAC.00962-07 17908942
22. Functional characterization of IScs605, an insertion element carried by tetracycline-resistant Chlamydia suis. J Dugan AA Andersen DD Rockey, Microbiology 2007 153 71 79 10.1099/mic.0.29253-0 17185536
23. Emergence of resistance to rifampin and rifalazil in Chlamydophila pneumoniae and Chlamydia trachomatis. A Kutlin S Kohlhoff P Roblin MR Hammerschlag P Riska, Antimicrob Agents Chemother 2005 49 903 907 10.1128/AAC.49.3.903-907.2005 15728882
24. Variation in the mutation frequency determining quinolone resistance in Chlamydia trachomatis serovars L2 and D. J Rupp W Solbach J Gieffers, J Antimicrob Chemother 2008 61 91 94 10.1093/jac/dkm447 18033786
25. Analysis of antibiotic resistance markers in Chlamydia trachomatis clinical isolates obtained after ineffective antibiotic therapy. MM Shkarupeta VN Lazarev TA Akopian TS Afrikanova VM Govorun, Bull Exp Biol Med 2007 143 713 717 10.1007/s10517-007-0221-9 18239808
26. First-choice antibiotics at subinhibitory concentrations induce persistence of Chlamydia pneumoniae. J Gieffers J Rupp A Gebert W Solbach M Klinger, Antimicrob Agents Chemother 2004 48 1402 1405 10.1128/AAC.48.4.1402- 1405.2004 15047553
27. Bactericidal activity of first-choice antibiotics against gamma interferon-induced persistent infection of human epithelial cells by Chlamydia trachomatis. N Reveneau DD Crane E Fischer HD Caldwell, Antimicrob Agents Chemother 2005 49 1787 1793 10.1128/AAC.49.5.1787-1793.2005 15855497
28. Pre-exposure of infected human endometrial epithelial cells to penicillin in vitro renders Chlamydia trachomatis refractory to azithromycin. PB Wyrick ST Knight, J Antimicrob Chemother 2004 54 79 85 10.1093/jac/dkh283 15163653
29. Outbreak and persistence of Chlamydia pneumoniae infection in an Italian family. L Migliorini V Canocchi G Zanelli M Valassina C Cellesi, Infez Med 2003 11 157 160 14985649
30. Chlamydia trachomatis persistence: an update. P Mpiga M Ravaoarinoro, Microbiol Res 2006 161 9 19 10.1016/j.micres.2005.04.004 16338585
31. Protein disulfide isomerase, a component of the estrogen receptor complex, is associated with Chlamydia trachomatis serovar E attached to human endometrial epithelial cells. CH Davis JE Raulston PB Wyrick, Infect Immun 2002 70 3413 3418 10.1128/IAI.70.7.3413-3418.2002 12065480
32. Disulfide-mediated interactions of the chlamydial major outer membrane protein: role in the differentiation of chlamydiae? T Hackstadt WJ Todd HD Caldwell, J Bacteriol 1985 161 25 31 2857160
33. Surface accessibility of the 70-kilodalton Chlamydia trachomatis heat shock protein following reduction of outer membrane protein disulfide bonds. JE Raulston CH Davis TR Paul JD Hobbs PB Wyrick, Infect Immun 2002 70 535 543 10.1128/IAI.70.2.535-543.2002 11796580
34. IFN-gamma induced persistent Chlamydia pneumoniae infection in HL and Mono Mac 6 cells: characterization by real-time quantitative PCR and culture. L Mannonen E Kamping T Penttila M Puolakkainen, Microb Pathog 2004 36 41 50 10.1016/j.micpath.2003.09.001 14643639
35. Three temporal classes of gene expression during the Chlamydia trachomatis developmental cycle. EI Shaw CA Dooley ER Fischer MA Scidmore KA Fields T Hackstadt, Mol Microbiol 2000 37 913 925 10.1046/j.1365-2958.2000. 02057.x 10972811
36. Use of a quantitative gene expression assay based on micro-array techniques and a mathematical model for the investigation of chlamydial generation time. DP Wilson S Mathews C Wan AN Pettitt DL McElwain, Bull Math Biol 2004 66 523 537 10.1016/j.bulm.2003.09.001 15006447
37. Mechanisms of host cell exit by the intracellular bacterium Chlamydia. K Hybiske RS Stephens, Proc Natl Acad Sci USA 2007 104 11430 11435 10.1073/pnas.0703218104 17592133
38. Response of Chlamydia trachomatis serovar E to iron restriction in vitro and evidence for iron-regulated chlamydial proteins. JE Raulston, Infect Immun 1997 65 4539 4547 9353031
39. Small molecule inhibitors of type III secretion in Yersinia block the Chlamydia pneumoniae infection cycle. L Bailey A Gylfe C Sundin S Muschiol M Elofsson P Nordstrom B Henriques-Normark R Lugert A Waldenstrom H Wolf-Watz S Bergstrom, FEBS Lett 2007 581 587 595 10.1016/j.febslet.2007.01.013 17257594
40. Rottlerin inhibits chlamydial intracellular growth and blocks chlamydial acquisition of sphingolipids from host cells. P Shivshankar L Lei J Wang G Zhong, Appl Environ Microbiol 2008 74 1243 1249 10.1128/AEM.02151-07 18083882
41. Treatment of Chlamydia trachomatis with a small molecule inhibitor of the Yersinia type III secretion system disrupts progression of the chlamydial developmental cycle. K Wolf HJ Betts B Chellas-Gery S Hower CN Linton KA Fields, Mol Microbiol 2006 61 1543 1555 10.1111/j.1365-2958.2006.05347.x 16968227
42. Selective cyclooxygenase inhibitors prevent the growth of Chlamydia pneumoniae in HL cells. Y Yan S Silvennoinen-Kassinen L Tormakangas M Leinonen P Saikku, Int J Antimicrob Agents 2008 32 78 83 10.1016/j.ijantimicag.2008.02.021 18524544
43. Identification of MEK- and phosphoinositide 3-kinase-dependent signalling as essential events during Chlamydia pneumoniae invasion of HEp2 cells. BK Coombes JB Mahony, Cell Microbiol 2002 4 447 460 10.1046/j.1462-5822.2002.00203. x 12102690
44. A small-molecule inhibitor of type III secretion inhibits different stages of the infectious cycle of Chlamydia trachomatis. S Muschiol L Bailey A Gylfe C Sundin K Hultenby S Bergstrom M Elofsson H Wolf-Watz S Normark B Henriques-Normark, Proc Natl Acad Sci USA 2006 103 14566 14571 10.1073/pnas.0606412103 16973741
45. Chlamydophila pneumoniae PknD exhibits dual amino acid specificity and phosphorylates Cpn0712, a putative type III secretion YscD homolog. DL Johnson JB Mahony, J Bacteriol 2007 189 7549 7555 10.1128/JB.00893-07 17766419
46. Expression of a Novel Protein Kinase Gene (Cpn0148) During the Replication Cycle of Chlamydia pneumoniae. JB Mahony DL Johnson BK Coombes X Song, Chlamydial Infections, International Symposium on Human Chlamydial Infections Antalya, Turkey. International Chlamydia Symposium, San Francisco, CA, Schachter J, Christiansen G, Clarke I, 2002 10 559 562
47. Characterization of the putative type III secretion ATPase CdsN (Cpn0707) of Chlamydophila pneumoniae. CB Stone DL Johnson DC Bulir JD Gilchrist JB Mahony, J Bacteriol 2008 190 6580 6588 10.1128/JB.00761-08 18708502
48. Activation of Raf/MEK/ERK/cPLA2 signaling pathway is essential for chlamydial acquisition of host glycerophospholipids. H Su G McClarty F Dong GM Hatch ZK Pan G Zhong, J Biol Chem 2004 279 9409 9416 10.1074/jbc.M312008200 14676189
49. Murine JAK3 is preferentially expressed in hematopoietic tissues and lymphocyte precursor cells. CB Gurniak LJ Berg, Blood 1996 87 3151 3160 8605329
50. JAK3: a novel JAK kinase associated with terminal differentiation of hematopoietic cells. SG Rane EP Reddy, Oncogene 1994 9 2415 2423 7518579
51. Regulation of JAK3 expression and activation in human B cells and B cell malignancies. PJ Tortolani BK Lal A Riva JA Johnston YQ Chen GH Reaman M Beckwith D Longo JR Ortaldo K Bhatia I McGrath J Kehrl J Tuscano DW McVicar JJ O'Shea, J Immunol 1995 155 5220 5226 7594533
52. Up-regulation of the JAK/STAT1 signal pathway during Chlamydia trachomatis infection. SP Lad EY Fukuda J Li LM de la Maza E Li, J Immunol 2005 174 7186 7193 15905563
53. The specificities of protein kinase inhibitors: an update. J Bain H McLauchlan M Elliott P Cohen, Biochem J 2003 371 199 204 10.1042/BJ20021535 12534346
54. The selectivity of protein kinase inhibitors: a further update. J Bain L Plater M Elliott N Shpiro CJ Hastie H McLauchlan I Klevernic JS Arthur DR Alessi P Cohen, Biochem J 2007 408 297 315 10.1042/BJ20070797 17850214
55. Specificity and mechanism of action of some commonly used protein kinase inhibitors. SP Davies H Reddy M Caivano P Cohen, Biochem J 2000 351 95 105 10.1042/0264-6021:3510095 10998351
56. Experimental Salmonella typhimurium infection in calves. C Wray WJ Sojka, Res Vet Sci 1978 25 139 143 364573
57. Spectrophotometric quantitation of tissue culture cell number in any medium. WA Mohler CA Charlton HM Blau, Biotechniques 1996 21 260 2, 264, 266 8862811